Loading viewer...
investor_presentation
Format: PDF investor_presentation
NASDAQ: XENE www.xenon -pharma.comCorporate Overview A U G U S T 2 0 2 2
NASDAQ: XENE www.xenon -pharma.comCorporate Overview
A U G U S T 2 0 2 2Forward Looking Statement/Safe Harbor
This slide presentation and the accompanying oral commentary contain forward -looking statements that involve risks, uncertaintie s and assumptions. If the risks or uncertainties
ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by suc h forward -looking statements. All statements other
than statements of historical fact could be deemed forward -looking, including, but not limited to, statements regarding research and clinical development plans and timelines; the
timing of and future results from clinical trials, including those related to XEN1101; the potential efficacy, safety profile , future development plans, addressable market, regulatory
success and commercial potential of XEN1101; the anticipated timing of IND, or IND -equivalent, submissions and the initiation of future clinical trials for XEN1101; the efficacy of
our clinical trial designs; our ability to successfully develop and achieve milestones in the XEN1101; the timing and results ofour interactions with regulators; and anticipated
enrollment in our clinical trials and the timing thereof.
These statements are based on estimates and information available to us at the time of this presentation and are not guarante es of future performance. Actual results could differ
materially from our current expectations as a result of many factors, including but not limited to: the impact of the COVID -19 p andemic on our business, research and clinical
development plans and timelines and results of operations, including impact on our clinical trial sites, collaborators, and c ontractors who act for or on our behalf, may be more
severe and more prolonged than currently anticipated; clinical trials may not demonstrate safety and efficacy of any of our o r our collaborators’ product candidates; promising
results from pre -clinical development activities or early clinical trial results may not be replicated in later clinical trials; our assumptions regarding our planned expenditures and
sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre -clinical efforts may not yield additi onal product candidates; any of our or our
collaborators’ product candidates, including XEN1101, may fail in development, may not receive required regulatory approvals, ormay be delayed to a point where they are not
commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies m ay impose additional requirements or delay the
initiation of clinical trials; regulatory agencies may be delayed in reviewing, commenting on or approving any of our or our collaborators’ clinical development plans as a result of
Preview truncated — download the full document for the complete content.
investor_presentation
15 Pages
investor_presentation
29 Pages
RPM International Inc.
investor_presentation
Erste Group
Kip McGrath Education Centres 2021 Investor Update
investor_presentationinvestor_presentation
11 Pages
Kip McGrath Education Centres Ltd